Advicenne's Revenue Surge in First Half of 2026

Advicenne has reported a significant increase in revenue for the first half of 2026. Net revenue more than doubled to €2.7 million, marking a 170% growth compared to the same period in 2025. This improvement follows the end of early access rebates, which adversely affected revenue in the past.

The company’s main products, Sibnayal® and Likozam®, contributed significantly to this growth. Sibnayal® sales in France saw a 41% increase in volume, while Likozam® benefitted from reimbursement, boosting its sales. Globally, Sibnayal®'s estimated sales reached €6.6 million, a 27% rise from 2025.

Advicenne's strategic moves have provided ample cash reserves until mid-2027, ensuring financial stability amid ongoing growth in the nephrology sector.